Early Morphic data hint at a threat to Entyvio
Hopes rise that Morphic might have cracked the conundrum of oral integrin inhibitors.
Merck gets on the Treg train with Pandion buy
Merck & Co pays $1.9bn for an intriguing but early approach in autoimmune disease.
Glaxo fails to win an Oscar
There might be a use for Glaxo’s anti-Covid-19 antibody otilimab in old patients, but repeating Actemra’s trick will not be easy.
Comirnaty is the real deal in the real world
Data from Israel’s real-world experience with Pfizer/Biontech’s Covid-19 vaccine should silence any doubters.
A three way battle beckons in GM1 gangliosidosis
Early data could give clues about whether gene therapies from Sio, Passage Bio or Lysogene will come out on top in this rare inherited disease.
